Acefylline
CAS 652-37-9
Acefylline (CAS 652-37-9) is a Phase 2 pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 39810.7 nM | 2 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
| - | Ki | 27600 nM | 1 | - |
| Adenosine receptor A2b GPCR |
Ki | 4.56 | - | Homo sapiens |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Acefylline used for in pharmaceutical contexts?
Acefylline (CAS 652-37-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Acefylline?
No adverse-event association or SIDER side-effect rows are rendered for Acefylline in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Acefylline also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Caffeine Carboxylic Acid with EU status "restricted".
What clinical phase is Acefylline in?
Acefylline is rendered with ChEMBL max phase 2.
What bioactivity targets are documented for Acefylline?
Acefylline has 4 bioactivity rows in this page query. Rendered target entries include Adenosine receptor A2b.